Literature DB >> 23156079

[Similarity of cycloprolylglycine to piracetam in antihypoxic and neuroprotective effects].

K N Kolisnikova, T A Gudasheva, G A Nazarova, T A Antipov, T A Voronina, S B Seredenin.   

Abstract

The antihypoxic activity of the endogenous cyclic dipeptide cycloprolylglycine (CPG) has been studied on a model of normobaric hypoxia with hypercapnia and its neuroprotective activity has been studied on a model of human neuroblastoma SH-SY5Y cell damage by 6-hydroxydopamine. It is established that CPG exhibits the antihypoxic activity at doses of 0.5 and 1.0 mg/kg (i.p.) on outbred and BALB/c mice, but not on C57B1/6 mice. The neuroprotective activity of CPG was detected in 10(-5) - 10(-8) M concentration range only when the treatment was carried out 24h before toxin introduction. The obtained data confirm the hypothesis that piracetam is a mimetic of the endogenous CPG neuropeptide.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23156079

Source DB:  PubMed          Journal:  Eksp Klin Farmakol        ISSN: 0869-2092


  3 in total

1.  Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.

Authors:  T A Gudasheva; K N Koliasnikova; T A Antipova; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2016-09-07       Impact factor: 0.788

2.  Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.

Authors:  T A Gudasheva; V V Grigoriev; K N Koliasnikova; V L Zamoyski; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2017-01-06       Impact factor: 0.788

Review 3.  Novel Technologies for Dipeptide Drugs Design and their Implantation.

Authors:  Tatiana A Gudasheva; Rita U Ostrovskaya; Sergey B Seredenin
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.